{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T02:40:23Z","timestamp":1777948823422,"version":"3.51.4"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,3]]},"DOI":"10.7759\/cureus.108171","type":"journal-article","created":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T20:57:18Z","timestamp":1777841838000},"source":"Crossref","is-referenced-by-count":0,"title":["Pembrolizumab-Induced Eruptive Keratoacanthomas Managed With Intralesional Corticosteroids: A Case Report"],"prefix":"10.7759","author":[{"given":"Kevin","family":"Varghese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Develyn","family":"Vetos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Woods","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesalyn","family":"Tate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Wang-Weinman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Pembrolizumab","author":"Flynn JP","year":"2026","unstructured":"Flynn JP, Gerriets V. Pembrolizumab. StatPearls [Internet]. StatPearls Publishing, Treasure Island, USA; 2026."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.06.006","article-title":"Pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 KEYNOTE-426 study","volume":"84","author":"Plimack ER","year":"2023","unstructured":"Plimack ER, Powles T, Stus V, et al.. Pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 KEYNOTE-426 study. Eur Urol. 2023, 84:449-54. 10.1016\/j.eururo.2023.06.006","journal-title":"Eur Urol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (Keytruda)","volume":"12","author":"Kwok G","year":"2016","unstructured":"Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Pembrolizumab (Keytruda). Hum Vaccin Immunother. 2016, 12:2777-89. 10.1080\/21645515.2016.1199310","journal-title":"Hum Vaccin Immunother"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2023.03.017","article-title":"Impact of therapy management on axitinib-related adverse events in patients with advanced renal cell carcinoma receiving first-line axitinib plus checkpoint inhibitor","volume":"21","author":"Zakharia Y","year":"2023","unstructured":"Zakharia Y, Huynh L, Du S, et al.. Impact of therapy management on axitinib-related adverse events in patients with advanced renal cell carcinoma receiving first-line axitinib plus checkpoint inhibitor. Clin Genitourin Cancer. 2023, 21:e343-51. 10.1016\/j.clgc.2023.03.017","journal-title":"Clin Genitourin Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-024-03694-7","article-title":"Eruptive keratoacanthoma secondary to immune checkpoint inhibitors: a narrative review","volume":"317","author":"Mager L","year":"2025","unstructured":"Mager L, Plaza JA, Sopkovich J, Kaffenberger BH, Dulmage B. Eruptive keratoacanthoma secondary to immune checkpoint inhibitors: a narrative review. Arch Dermatol Res. 2025, 317:234. 10.1007\/s00403-024-03694-7","journal-title":"Arch Dermatol Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2019.03.014","article-title":"Eruptive squamous cell carcinomas in metastatic melanoma: an unintended consequence of immunotherapy","volume":"5","author":"Haraszti S","year":"2019","unstructured":"Haraszti S, Polly S, Ezaldein HH, Rothbaum R, Delost GR, Beveridge M. Eruptive squamous cell carcinomas in metastatic melanoma: an unintended consequence of immunotherapy. JAAD Case Rep. 2019, 5:514-7. 10.1016\/j.jdcr.2019.03.014","journal-title":"JAAD Case Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.0989","article-title":"Eruptive keratoacanthomas associated with pembrolizumab therapy","volume":"153","author":"Freites-Martinez A","year":"2017","unstructured":"Freites-Martinez A, Kwong BY, Rieger KE, Coit DG, Colevas AD, Lacouture ME. Eruptive keratoacanthomas associated with pembrolizumab therapy. JAMA Dermatol. 2017, 153:694-7. 10.1001\/jamadermatol.2017.0989","journal-title":"JAMA Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15614","article-title":"Development of cutaneous squamous cell carcinoma during pembrolizumab therapy","volume":"48","author":"Mizutani K","year":"2021","unstructured":"Mizutani K, Nakanishi T, Ikejiri M, et al.. Development of cutaneous squamous cell carcinoma during pembrolizumab therapy. J Dermatol. 2021, 48:e7-8. 10.1111\/1346-8138.15614","journal-title":"J Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3301","article-title":"Multiple keratoacanthoma-like lesions in a patient treated with pembrolizumab","volume":"99","author":"Fradet M","year":"2019","unstructured":"Fradet M, Sibaud V, Tournier E, et al.. Multiple keratoacanthoma-like lesions in a patient treated with pembrolizumab. Acta Derm Venereol. 2019, 99:1301-2. 10.2340\/00015555-3301","journal-title":"Acta Derm Venereol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.43402","article-title":"Pembrolizumab-induced eruptive keratoacanthomas and lichen planus in a lung cancer patient","volume":"15","author":"Tembunde Y","year":"2023","unstructured":"Tembunde Y, Dika MN. Pembrolizumab-induced eruptive keratoacanthomas and lichen planus in a lung cancer patient. Cureus. 2023, 15:e43402. 10.7759\/cureus.43402","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/486394-pembrolizumab-induced-eruptive-keratoacanthomas-managed-with-intralesional-corticosteroids-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T20:57:18Z","timestamp":1777841838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/486394-pembrolizumab-induced-eruptive-keratoacanthomas-managed-with-intralesional-corticosteroids-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,3]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.108171","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,3]]}}}